Science and vision

See what’s new in the field of hereditary eye diseases

Blog managed by the DBGen team, with updated therapies, news and events involving hereditary eye diseases. We invite you to take part in this forum.

Filters

Subscribe to our blog

DBGen awarded an EASI-Genomics grant for innovative long-read sequencing of inherited retinal dystrophies

DBGenGenetic diagnosisScience and vision
The Transnational Access Committee of the European Advanced infraStructure for Innovative Genomics (EASI-Genomics) has selected the project PID15251 submitted by DBGen Ocular Genomics in the third call for projects of this initiative. DBGen’s proposal has successfully passed the scientific and technical evaluation steps of this highly competitive call. EASI-Genomics is an initiative, funded with 10 million euros by the European Union through the Horizon...
leer mas

Promising results for a first-in-class Usher syndrome IIA therapy

Retinitis pigmentaryScience and visionTherapyUsher's syndrome
The Dutch biotechnology company ProQR has just presented (March 2021) the first results of a clinical trial, named Stellar, with QR-421a, an antisense oligonucleotide designed to stop vision loss or restore vision in Usher syndrome IIA and non-syndromic retinitis pigmentosa patients due to USH2A exon 13 mutations. The therapeutical approach aims to exclude the exon 13 coding region in the messenger RNA (exon skipping) and,...
leer mas

LHON gene therapy affords sustained improvement in visual acuity paving the way to approval

Gene therapyScience and vision
The biopharma company GenSight Biologics, specialized in developing gene therapies for retinal degenerative diseases, recently published results of two Phase III clinical trials on the effect of LUMEVOQ gene therapy for Leber Hereditary Optic Neuropathy (LHON) patients. In September 2020, GenSight requested approval of LUMEVOQ to the European Medicines Agency (EMA) to treat LHON patients carrying a mutation in the ND4 mitochondrial gene. LHON is...
leer mas

Optogenetic therapy to restore advanced vision loss in retinal dystrophies

Gene therapyRetinal dystrophyScience and vision
Gene therapies currently under study for retinal dystrophies are administered when viable photoreceptor able to be rescued at the functional level still remain. Most therapies are gene-specific and, in some cases, mutation-specific. In advanced disease stages, when a large number of photoreceptor cells have degenerated, the probability of success of these therapies is very low. Therefore, researchers are exploring methodologies to...
leer mas

Encouraging results from achromatopsia gene therapy trials

AchromatopsiaGene therapyScience and vision
Achromatopsia is a disorder that affects one in every 30,000 people and is characterized by the partial or total absence of colour vision due to lack of function of cones, one type of retinal cells. Achromatopsia patients have other visual problems such as extreme sensitivity to light (photophobia), uncontrollable and involuntary eye movements (nystagmus) and decreased visual acuity. Achromatopsia is a...
leer mas

Progress in anti-VEGF gene therapy for age-related macular degeneration

Gene therapyMacular degenerationScience and vision
Age-related macular degeneration (AMD) is one of the most common disease of the retina and the main cause of vision loss in adults over 60 years. It is estimated that 3 million people worldwide are affected, and its incidence increases as life expectancy grows in developed countries. AMD is a progressive disease that affects the macula, the area near the centre of...
leer mas